Scholarlink

<p>VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) is a recently identified clonal disorder caused by somatic <i>UBA1</i> mutations in hematopoietic stem cells, leading to bone marrow failure (BMF) and systemic inflammation. We screened 1771 patients with BMF who underwent unrelated hematopoietic cell transplantation in Japan between 1995 and 2020 using multitarget real-time PCR. The diagnoses included myelodysplastic syndrome (MDS, <i>n</i> = 1139), myeloproliferative neoplasms (<i>n</i> = 125), plasma cell neoplasms (<i>n</i> = 23), acquired BMF (<i>n</i> = 395), and congenital BMF (<i>n</i> = 89). Pathogenic <i>UBA1</i> mutations were detected in two male patients with MDS (aged 48 and 63&#xa0;years), corresponding to a prevalence of 0.11% in the overall cohort and 0.18% in MDS cases; an additional 70-year-old male was diagnosed outside of the cohort. All three underwent unrelated bone marrow transplantation following fludarabine and busulfan-based conditioning. The first and third patients died of idiopathic pneumonia syndrome 5 and 28&#xa0;months after transplantation. In the third patient, <i>UBA1</i>-mutant cells persisted at low frequency in skin graft-versus-host disease tissue despite clearance from his blood. The second patient survived without relapse or graft-versus-host disease at 28&#xa0;months. Although VEXAS syndrome is rare among unrelated HCT recipients with malignant and non-malignant BMF in the historical cohort, HCT is positioned as a potentially curative, yet high-risk strategy. Additional studies are essential to refine patient selection, optimize transplant timing, and improve management strategies to mitigate risk and enhance survival. Therefore, the role of tissue-residual <i>UBA1</i>-mutant clones in post-transplant complications warrants further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence and outcome of VEXAS syndrome in unrelated hematopoietic cell transplantation for bone marrow failure

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月22日

查看全文
  • Yoshitaka Zaimoku,
  • Tatsuya Imi,
  • Tatsuya Hatada,
  • Hiroki Mizumaki,
  • Hiroki Mura,
  • Hiroki Yoshino,
  • Yui Kano,
  • Miku Kobayashi,
  • Eriko Morishita,
  • Natsumi Fushida,
  • Takashi Matsushita,
  • Keishi Mizuguchi,
  • Hiroko Ikeda,
  • Yasuhito Nannya,
  • Seishi Ogawa,
  • Kazuyoshi Hosomichi,
  • Noriko Doki,
  • Yuta Katayama,
  • Takashi Koike,
  • Ken-ichi Matsuoka,
  • Tetsuya Nishida,
  • Yoshiyuki Takahashi,
  • Keisuke Kataoka,
  • Hideyuki Nakazawa,
  • Yasunori Ueda,
  • Takahiro Fukuda,
  • Tatsuo Ichinohe,
  • Fumihiko Ishimaru,
  • Makoto Onizuka,
  • Yoshiko Atsuta,
  • Toshihiro Miyamoto

摘要

VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) is a recently identified clonal disorder caused by somatic UBA1 mutations in hematopoietic stem cells, leading to bone marrow failure (BMF) and systemic inflammation. We screened 1771 patients with BMF who underwent unrelated hematopoietic cell transplantation in Japan between 1995 and 2020 using multitarget real-time PCR. The diagnoses included myelodysplastic syndrome (MDS, n = 1139), myeloproliferative neoplasms (n = 125), plasma cell neoplasms (n = 23), acquired BMF (n = 395), and congenital BMF (n = 89). Pathogenic UBA1 mutations were detected in two male patients with MDS (aged 48 and 63 years), corresponding to a prevalence of 0.11% in the overall cohort and 0.18% in MDS cases; an additional 70-year-old male was diagnosed outside of the cohort. All three underwent unrelated bone marrow transplantation following fludarabine and busulfan-based conditioning. The first and third patients died of idiopathic pneumonia syndrome 5 and 28 months after transplantation. In the third patient, UBA1-mutant cells persisted at low frequency in skin graft-versus-host disease tissue despite clearance from his blood. The second patient survived without relapse or graft-versus-host disease at 28 months. Although VEXAS syndrome is rare among unrelated HCT recipients with malignant and non-malignant BMF in the historical cohort, HCT is positioned as a potentially curative, yet high-risk strategy. Additional studies are essential to refine patient selection, optimize transplant timing, and improve management strategies to mitigate risk and enhance survival. Therefore, the role of tissue-residual UBA1-mutant clones in post-transplant complications warrants further investigation.